ATM mutation

News alerts, weekly reports and conference planners

Entrez ID:

472

Related biomarkers:

‹

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® Liquid CDx (21)

FoundationOne® CDx (110)

FoundationOne® Liquid CDx (21)

ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
ATM mutation	Squamous Cell Carcinoma of Head and Neck	ATM mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
ATM mutation	Ovarian Cancer	ATM mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
ATM mutation	Lung Adenocarcinoma	ATM mutation	Lung Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Cancer	ATM mutation	Pancreatic Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Urothelial Cancer	ATM mutation	Urothelial Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Biliary Tract Cancer	ATM mutation	Biliary Tract Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
ATM mutation	HER2 Negative Breast Cancer	ATM mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
ATM mutation	Biliary Tract Cancer	ATM mutation	Biliary Tract Cancer	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
ATM mutation	Colorectal Cancer	ATM mutation	Colorectal Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3	BAY 1895344 Sensitive: C3 – Early Trials BAY 1895344 Sensitive : C3
ATM mutation	Gastroesophageal Junction Adenocarcinoma	ATM mutation	Gastroesophageal Junction Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ATM mutation	Gastric Adenocarcinoma	ATM mutation	Gastric Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ATM mutation	Colon Cancer	ATM mutation	Colon Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ATM mutation	Mantle Cell Lymphoma	ATM mutation	Mantle Cell Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
ATM mutation	Squamous Cell Carcinoma of Head and Neck	ATM mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3	GnRH stimulant Resistant: C3 – Early Trials GnRH stimulant Resistant : C3
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	durvalumab + gemcitabine + tremelimumab Sensitive: C3 – Early Trials durvalumab + gemcitabine + tremelimumab Sensitive : C3	durvalumab + gemcitabine + tremelimumab Sensitive: C3 – Early Trials durvalumab + gemcitabine + tremelimumab Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	avelumab Sensitive: C3 – Early Trials avelumab Sensitive : C3	avelumab Sensitive: C3 – Early Trials avelumab Sensitive : C3
ATM mutation	Ovarian Cancer	ATM mutation	Ovarian Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3	olaparib + AZD6738 Sensitive: C3 – Early Trials olaparib + AZD6738 Sensitive : C3
ATM mutation	Non Small Cell Lung Cancer	ATM mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

ATM mutation

Associations